1 / 13

Teva Pharmaceutical Industries, Ltd

Teva Pharmaceutical Industries, Ltd. Cassandra Gissal Wendy Krueger Nick Maglio Sue Mathis Nicole Schumann. Agenda. Main Issues Background Pharmaceutical Firms Generic Pharmaceutical Firms – US Generic Pharmaceutical Firms – World Competitors Alternatives Recommendations

hedley-osborn
Télécharger la présentation

Teva Pharmaceutical Industries, Ltd

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Teva Pharmaceutical Industries, Ltd Cassandra Gissal Wendy Krueger Nick Maglio Sue Mathis Nicole Schumann

  2. Agenda Main Issues Background Pharmaceutical Firms Generic Pharmaceutical Firms – US Generic Pharmaceutical Firms – World Competitors Alternatives Recommendations Conclusions Questions

  3. Main Issues Teva Pharmaceutical Industries, Ltd’s sales are declining Generic Pharmaceutical competitors are steadily growing Low cost and Innovation

  4. Teva Pharmaceutical Industries, Ltd Background Teva was established in 1901 in Jerusalem Since 1985 – Executed 14 mergers worth $12 billion Worlds largest leading producer of generic pharmaceuticals 2006 – Controlled 18% of the base U.S. generics market by number of prescriptions

  5. Pharmaceutical Firms • In 2006, the pharmaceutical industry totaled $600 billion worldwide • Growth depends on patent protection • 12% growth over the last 5 years • 20% return on equity • Valued on: • Pipeline of new drugs in pre-approval stages • Projected lifespan of drugs currently on the market • Annual industry growth was predicted to slow to 5%-8% annually

  6. Generic Pharmaceuticals Bioequivalent version of name brand counterparts Priced lower than name brand drugs US is the largest generics market Manufactured and sold if the original drugs were not projected by patents Subject to the same regulatory standards Growth was expected to grow 6% faster than their name brand competitors

  7. Generic Pharmaceuticals - World

  8. Generic Competitors Novartis –acquired 2 generic companies Low-cost firms from India and Eastern Europe are growing Generic drugs were released by innovative firms

  9. Generic Products • Commodity generics • Tablet or capsule form • Most competitors are within this market • Niche generics • Drugs whose active molecules are difficult to systhezise • Higher gross margins • Biosimilars • Difficult to replicate drugs • Multibillion dollar market

  10. Alternatives

  11. Recommendations

  12. Conclusion

  13. Questions?

More Related